BEIJING, Nov 14 — China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.
GLP-1 drugs aid weight loss by mimicking a natural gut hormone that suppresses appetite and regulates blood sugar levels.
The medication has soared in popularity in recent years, with drug makers now competing to release pills as an alternative to existing injection treatments.
China’s National Medical Products Administration (NMPA) said Thursday it had approved US-based pharmaceutical giant Eli Lilly’s pills, marketed as ‘Muyouda’, to treat obese or overweight adults with at least one weight-related condition.
